Immune Reconstitution in naïve HIV Patients With CD4 <100 Cells/mL When Treated With Lopinavir or Efavirenz.

This study has been terminated.
Information provided by:
Hospital Clinic of Barcelona Identifier:
First received: October 10, 2006
Last updated: NA
Last verified: October 2006
History: No changes posted

October 10, 2006
October 10, 2006
Not Provided
Not Provided
Proportion of patients with viral load below 20 copies/ml in plasma and lymphoid tissue at 12 months.
Same as current
No Changes Posted
  • Degree and kinetics of recovery of the immune system.
  • New CDC C events
  • Mortality
Same as current
Not Provided
Not Provided
Immune Reconstitution in naïve HIV Patients With CD4 <100 Cells/mL When Treated With Lopinavir or Efavirenz.
A Randomized, Pilot Study on the Antiviral Activity and Immunological Effects of Lopinavir/Ritonavir vs. Efavirenz in Treatment-naïve HIV-Infected Patients With CD4 Cell Counts Below 100 Cells/mm3
Pilot, randomized, parallel, open-label, controlled, clinical study evaluating virological response in plasma and extra-plasmatic compartments, together with the degree and kinetics of immune reconstitution in treatment-naïve patients with CD4 count below 100 cells/mL, when treated with tenofovir and abacavir together with lopinavir or efavirenz.
Not Provided
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
HIV Infection
  • Drug: tenofovir + abacavir + lopinavir/ritonavir
  • Drug: tenofovir + abacavir + efavirenz
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
Not Provided

Inclusion Criteria:

  • HIV-infection
  • Antiretroviral-naive
  • CD4 cell count below 100 cells/mm3

Exclusion Criteria:

  • Pregnancy
  • Current opportunistic infection requiring parenteral therapy
  • Current malignancies requiring parenteral chemotherapy
  • Any contraindication to the study drugs
18 Years and older
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Hospital Clinic of Barcelona
Not Provided
Study Chair: Josep M Gatell, MD Hospital Clinic de Barcelona
Hospital Clinic of Barcelona
October 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP